SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0000947871-21-000393
Filing Date
2021-03-26
Accepted
2021-03-26 16:06:51
Documents
2
Group Members
ORBIMED ISRAEL GP LTD.

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13D ss195164_sc13d.htm SC 13D 80039
2 JOINT FILING AGREEMENT ss195164_ex9901.htm EX-99.1 5727
  Complete submission text file 0000947871-21-000393.txt   87501
Mailing Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002
Business Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002 972-77-331-0156
Chemomab Therapeutics Ltd. (Subject) CIK: 0001534248 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-86953 | Film No.: 21777358
SIC: 2834 Pharmaceutical Preparations

Mailing Address 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 1022-4629
Business Address 89 MEDINAT HAYEHUDIM STREET, 11TH FLOOR HERZLIYA L3 46766 212-739-6400
OrbiMed Israel BioFund GP Limited Partnership (Filed by) CIK: 0001569821 (see all company filings)

IRS No.: 980697985 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: SC 13D